Economic burden of hepatitis B infection among patients with diabetes

References

• Schillie SF, Xing J, Murphy TV, Hu DJ. Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999-2010. J Viral Hepatitis 2012; 19:674-676; http://dx.doi.org/10.1111/j.1365-2893.2012.01616.x
   PubMed Web of Science ®Google Scholar
• Reilly ML, Schillie SF, Smith E, Poissant T, Vonderwahl CW, Gerard K, Baumgartner J, Mercedes L, Sweet K, Muleta D, et al. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus. J Diabet Sci Tech 2012; 6:858-866; http://dx.doi.org/10.1177/193229681200600417
   PubMedGoogle Scholar
• El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126(2):460-468; PMID:14762783; http://dx.doi.org/10.1053/j.gastro.2003.10.065
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Schillie S, Wittenborn JS, Bradley CL, Zhou F, Byrd K, Murphy TV. Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. Diabetes Care 2013; 36:63-69; PMID:22933435; http://dx.doi.org/10.2337/dc12-0759
   PubMed Web of Science ®Google Scholar
• Bond WW, Favero MS, Peterson NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981; 9:550-551; http://dx.doi.org/10.1016/S0140-6736(81)92877-4
   Google Scholar
• Favero MS, Bond WW, Peterson NJ, Berquist KR, Maynard JE. Detection methods for study of the stability of hepatitis B antigen on surfaces. J Infect Dis 1974; 129:210-212; PMID:4810942; http://dx.doi.org/10.1093/infdis/129.2.210
   PubMed Web of Science ®Google Scholar
• Sawyer MH, Hoerger TJ, Murphy TV, Schillie SF, Hu D, Spradling PR, Byrd KK, Xing J, Reilly ML, Tohme RA, et al. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60:1709-1711; PMID:22189894
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60(50):1709-1711; PMID:22189894
   PubMedGoogle Scholar
• Williams WW, Lu PJ, O'Halloran A, Bridges CB, Kim DK, Pilishvili T, Hales CM, Markowitz LE. Vaccination coverage among adults, excluding influenza vaccination—United States, 2013. MMWR Morb Mortal Wkly Rep 2015; 64(4):95-102; PMID:25654611
   PubMed Web of Science ®Google Scholar
• Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004; 38:S144-S147; PMID:15602162; http://dx.doi.org/10.1097/00004836-200411003-00005
   PubMed Web of Science ®Google Scholar
• Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008; 26:937-949; PMID:18850763; http://dx.doi.org/10.2165/00019053-200826110-00006
   PubMed Web of Science ®Google Scholar
• Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: comparison of current treatment guidelines. World J Gasteroenterol 2012; 18:6106-6113; http://dx.doi.org/10.3748/wjg.v18.i42.6106
   PubMed Web of Science ®Google Scholar
• Park JY, Heo J, Lee TJ, Yim HJ, Yeon JE, Lim Y-S, Seo MJ, Ahn SH, Lee MS. A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PloS One 2013; 8:e57900; PMID:23536775; http://dx.doi.org/10.1371/journal.pone.0057900
   PubMedGoogle Scholar
• Tunceli O, Wade R, Gu T, Bouchard JR, Aagren M, Luo W. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods. Curr Med Res Opin 2010; 26:1827-1834; PMID:20491613; http://dx.doi.org/10.1185/03007995.2010.488544
   PubMed Web of Science ®Google Scholar
• Gandra SR, Lawrence LW, Parasuraman BM, Darin RM, Sherman JJ, Wall JL. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm 2006; 12:546-554; PMID:16981800
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008; 6:103-112; PMID:19231904; http://dx.doi.org/10.1007/BF03256126
   PubMedGoogle Scholar
• Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm 2009; 15:312-322.
   PubMed Web of Science ®Google Scholar
• Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm 2006; 12:130-142; PMID:16515371
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika 1983; 70(1):41-55; http://dx.doi.org/10.1093/biomet/70.1.41
   Web of Science ®Google Scholar
• Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Cary, NC: SAS Institute, Inc., 2001 ; cited 2014 Dec 2. Available from: http://www2.sas.com/proceedings/sugi26/p214-26.pdf.
   Google Scholar
• Parsons LS. Using SAS software to perform a case-control match on propensity score in an observational study. In: Proceedings of the Thirtieth Annual SAS Users Group International Conference. Cary, NC: SAS Institute, Inc., 2005 ; cited 2014 Dec 2. Available from: http://www2.sas.com/proceedings/sugi25/25/po/25p225.pdf.
   Google Scholar
• Chang HY, Weiner JP, Richards TM, Bliech SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 2012; 18(11):721-726; PMID:23198714
   PubMed Web of Science ®Google Scholar
• Chang HY, Weiner JP, Richards RM, Bliech SN, Segal JB. Predicting costs with Diabetes Complications Severity Index in claims data. Am J Manag Care 2012; 18(4):213-219; PMID:22554010
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17(7):531-546; PMID:21870894
   PubMed Web of Science ®Google Scholar
• United States Department of Labor, Bureau of Labor Statistics. Consumer price index; cited 2014 Sep 17. Available from http://www.bls.gov/cpi/home.htm.
   Google Scholar
• Vagula M, Devi SS. Hepatotoxicity of antidiabetic drugs. US Pharm 2008; 33(5 Diabetes Suppl):3-9
   Google Scholar